F11R Antibody

What is F11R and why is it an important research target?

F11R (F11 Receptor), also known as Junctional Adhesion Molecule-A (JAM-A) or JAM-1, is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. It is primarily located in epithelial and endothelial cell tight junctions and is also expressed on circulating platelets and leukocytes . F11R plays crucial roles in multiple biological processes including paracellular permeability regulation, tight junction formation and maintenance, leukocyte transendothelial migration, epithelial-to-mesenchymal transition, angiogenesis, and platelet activation . Its involvement in cancer progression, inflammatory processes, and cardiovascular diseases makes it a significant target for therapeutic intervention and biomarker development .

What are the structural characteristics of the F11R protein that researchers should be aware of?

F11R contains two immunoglobulin-like domains: an N-terminal membrane-distal V-type Ig-like domain (D1 domain, S28-K125) involved in homophilic binding, and a membrane-proximal C2-type Ig-like domain (D2 domain, P135-R228) that participates in heterophilic interactions . The D1 domain has two critical structural motifs: the cis-dimerization motif (R59V60E61) and trans-dimerization motif (N43N44P45), both involved in F11R adhesive interactions . The D2 domain contains a single N-glycan at N185 residue that stabilizes F11R homodimers. This N-glycosylation is fundamental for its functions, including reduction in cell migration, increased Rap1 activity, barrier function intensification, and regulation of leukocyte adhesion .

How do F11R expression patterns differ between normal and pathological states?

Under physiological conditions, healthy endothelium expresses low levels of F11R-mRNA, with the F11R protein primarily residing within endothelial tight junctions . In contrast, when endothelial cells are exposed to proinflammatory cytokines like TNF-α and/or IFN-γ, F11R-mRNA levels rise significantly, followed by increased de-novo synthesis of the F11R protein and insertion of newly-synthesized F11R molecules into the luminal surface of the endothelium . This alteration in expression and localization is critical in pathological processes such as atherosclerosis and cancer metastasis . In cancer contexts, both overexpression and downregulation of F11R have been observed depending on the cancer type, suggesting tissue-specific roles in tumorigenesis .

What are the recommended methods for detecting F11R protein expression in different cell types?

Several complementary techniques are recommended for comprehensive F11R protein detection:

• Western blotting: Effective for quantifying total F11R protein levels in cell lysates. Use anti-F11R antibodies following standard SDS-PAGE protocols. Quantification can be performed using image analysis software like Image J, normalizing to housekeeping proteins such as tubulin .

• Flow cytometry: Optimal for assessing cell surface expression of F11R. Cells can be labeled with FITC anti-human CD321 (F11R/JAM-A) Mouse IgG1 Antibody or relevant isotype controls. Analysis should be performed upon fluorescence excitation at 488 nm and emission at 517 nm .

• Immunofluorescence microscopy: Useful for determining subcellular localization of F11R, particularly to distinguish between junctional and luminal surface expression.

• ELISA: Appropriate for measuring soluble F11R/JAM-A (sJAM-A) in biological fluids such as plasma .

Each method provides distinct and complementary information about F11R expression, localization, and processing.

What is the optimal protocol for quantifying F11R mRNA expression in endothelial cells?

For accurate quantification of F11R mRNA in endothelial cells, real-time PCR (qPCR) is the method of choice. The protocol includes:

• Cell preparation: Grow endothelial cells (e.g., HAEC or HUVEC) to confluence and treat with cytokines if studying inflammation effects.

• RNA extraction: Wash cells with PBS, lyse them, and extract total RNA using a high-quality RNA isolation kit (e.g., RNeasy Mini Kit).

• Reverse transcription: Convert RNA to cDNA using reverse transcriptase.

• qPCR setup: Use F11R-specific primers and probes. Based on published research, recommended primers are:

  • Forward primer (740): CCG TCC TTG TAA CCC TGA TT

  • Reverse primer (818): CTC CTT CAC TTC GGG CAC TA

  • Probe (788): TGG CCT CGG CTA TAG GCA AAC C

• Thermal cycling: Typical conditions include 1 cycle at 48°C for 30 min, 10 min at 95°C, followed by 40 cycles of 15 sec at 95°C and 1 min at 60°C .

• Data analysis: Express F11R mRNA levels as a ratio to a housekeeping gene like GAPDH. Calculate using a standard curve derived from reference RNA .

This protocol allows for sensitive and reproducible quantification of F11R mRNA levels, crucial for studying its regulation under various experimental conditions.

How can researchers effectively silence F11R expression for functional studies?

For effective silencing of F11R expression, small interfering RNA (siRNA) technology is highly recommended. The methodology involves:

• siRNA design: Design specific siRNAs targeting conserved regions of the F11R gene. Multiple siRNAs should be tested to identify those with highest knockdown efficiency.

• Transfection optimization: Determine optimal transfection conditions for your cell type of interest. For endothelial cells, lipid-based transfection reagents are commonly used, but electroporation may provide better efficiency for certain cell types.

• Validation of knockdown: Confirm silencing efficiency at both mRNA level (using qRT-PCR) and protein level (using Western blot) at 48-72 hours post-transfection.

• Functional assays: After confirming knockdown, proceed with functional studies such as transendothelial migration assays, adhesion assays, or barrier function tests.

• Controls: Always include appropriate controls:

  • Non-targeting siRNA control to account for non-specific effects

  • Untransfected cells to assess baseline expression

  • Positive control siRNA targeting a housekeeping gene

This approach allows for specific inhibition of F11R expression, enabling researchers to evaluate its precise role in various cellular processes .

How does F11R contribute to breast cancer metastasis, and what experimental models are most appropriate to study this relationship?

F11R/JAM-A plays a significant role in breast cancer metastasis through multiple mechanisms. It facilitates transendothelial migration of breast cancer cells, a critical step in the metastatic cascade . Research indicates that tumor inducers like thymosin β4 (Tβ4) and TGF-β1 reduce soluble JAM-A levels in plasma and decrease F11R/JAM-A protein levels in human microvascular endothelial cells, potentially promoting cancer cell adhesion and migration .

The most appropriate experimental models include:

• In vitro models:

  • Transendothelial migration (TEM) assays using human mammary epithelial cell lines and endothelial cell monolayers

  • Adhesion assays between breast cancer cells and endothelium

  • Endothelial permeability studies using fluorescent tracer assays and Real-Time Cell Analysis (RTCA)

• In vivo models:

  • Mouse 4T1 breast cancer model, which closely mimics human breast cancer progression

  • Xenograft models using human breast cancer cell lines with manipulated F11R expression

• Molecular interventions:

  • F11R antagonistic peptides like peptide 4D (P4D), which blocks homophilic interactions between F11R molecules

  • Anti-F11R/JAM-A monoclonal antibodies, which have demonstrated reduction in murine breast tumor xenograft growth

These models allow researchers to assess the effects of F11R inhibition on different stages of breast cancer metastasis and provide insights into potential therapeutic strategies targeting this protein .

What are the conflicting findings regarding F11R expression in different cancer types, and how might researchers address these contradictions?

Research indicates that F11R exhibits tissue-dependent roles in tumorigenesis, with apparently contradictory findings across different cancer types. While some studies suggest that F11R has pro-tumorigenic effects (particularly in breast cancer), others indicate anti-tumorigenic roles in certain contexts .

These contradictions might be addressed through:

• Tissue-specific analysis: Systematic comparison of F11R expression and function across multiple cancer types in parallel experimental settings. This approach can identify tissue-specific cofactors that might explain divergent outcomes.

• Signaling pathway elucidation: Comprehensive investigation of downstream signaling pathways activated by F11R in different cellular contexts. Techniques like phosphoproteomics, RNA-seq, and pathway inhibition studies can reveal how the same protein triggers different cellular responses.

• Isoform analysis: Examination of potential F11R splice variants or post-translationally modified forms that might exist in different cancer types.

• Microenvironmental considerations: Analysis of how tumor microenvironment factors might modulate F11R function, potentially explaining contradictory findings.

• Temporal dynamics: Investigation of F11R's role at different stages of cancer progression, as its function may change during tumor evolution.

How does the inflammatory regulation of F11R contribute to atherosclerosis, and what experimental approaches best demonstrate this relationship?

F11R plays a critical role in atherosclerosis through inflammation-mediated mechanisms. Under inflammatory conditions, pro-inflammatory cytokines (TNF-α and IFN-γ) induce de-novo transcription and translation of F11R in endothelial cells, leading to its insertion into the luminal surface of the endothelium . This newly expressed F11R then engages in homophilic interactions with F11R molecules constitutively present on circulating platelets, resulting in platelet adhesion to the inflamed endothelium - a crucial early step in atherogenesis that precedes atherosclerotic plaque formation in non-denuded blood vessels .

The most effective experimental approaches to demonstrate this relationship include:

• In vitro inflammatory models:

  • Cytokine-stimulated endothelial cell cultures (using TNF-α, IFN-γ) to induce F11R expression

  • Platelet adhesion assays to measure interaction between platelets and inflamed endothelium

  • Molecular inhibition studies using RNA synthesis inhibitors (e.g., actinomycin D) or specific F11R-siRNAs to block F11R expression

• Molecular techniques:

  • Real-time PCR to quantify F11R mRNA expression in response to inflammatory stimuli

  • Western blotting to measure F11R protein levels

  • Immunofluorescence microscopy to visualize F11R redistribution to the luminal surface

• Analysis of signaling pathways:

  • Inhibitors of NF-κB and JAK/STAT pathways to elucidate mechanisms of cytokine-induced F11R expression

  • Examination of downstream effectors of F11R signaling in vascular cells

These approaches collectively demonstrate the mechanistic connection between inflammation, F11R expression, platelet adhesion, and the initiation of atherosclerosis .

What is the significance of soluble F11R/JAM-A (sJAM-A) levels in plasma, and how should researchers properly collect and analyze these samples?

Soluble F11R/JAM-A (sJAM-A) levels in plasma serve as potential biomarkers for various pathological conditions. Research has shown that tumor inducers like thymosin β4 (Tβ4) and TGF-β1 can reduce sJAM-A levels in murine plasma, suggesting its relevance in cancer progression . Changes in sJAM-A levels may reflect alterations in endothelial barrier function, inflammatory status, or tumor activity.

For proper collection and analysis of sJAM-A samples:

• Sample collection:

  • Collect blood in anticoagulant tubes appropriate for plasma preparation (e.g., EDTA or citrate tubes)

  • Process samples consistently with standardized centrifugation protocols to obtain plasma

  • Aliquot samples to avoid freeze-thaw cycles

  • Store at -80°C for long-term preservation

• Analysis methods:

  • ELISA is the recommended method for quantifying sJAM-A in plasma samples

  • Use commercially validated ELISA kits specific for F11R/JAM-A or develop in-house assays with rigorously tested antibodies

  • Include appropriate standards and controls in each assay run

• Data interpretation considerations:

  • Establish normal reference ranges from healthy controls

  • Account for potential confounding factors such as age, sex, and comorbidities

  • Consider the timing of sample collection relative to disease progression or treatment

  • Normalize data appropriately when comparing across multiple studies

• Complementary analyses:

  • Correlate sJAM-A levels with other inflammatory markers

  • Consider paired analysis with tissue expression of F11R when possible

This comprehensive approach ensures reliable and reproducible measurement of sJAM-A, enabling its effective use as a biomarker in research and potentially clinical settings .

How can F11R-derived peptides be developed as therapeutic agents, and what preclinical validation steps are essential?

F11R-derived peptides, particularly peptide 4D (P4D) which blocks homophilic interactions between F11R molecules, show promise as therapeutic agents for conditions like breast cancer metastasis . The development and validation process should include:

• Peptide design and optimization:

  • Structure-based design targeting specific F11R interaction domains

  • Sequence optimization for stability, half-life, and cell penetration

  • Development of multiple candidate peptides based on different F11R epitopes

• In vitro functional validation:

  • Binding affinity assays to confirm target engagement

  • Functional assays demonstrating inhibition of:

    • Transendothelial migration of cancer cells

    • Adhesion of cancer cells to endothelium

    • Platelet-endothelial cell interactions

  • Specificity testing against related adhesion molecules

• Mechanism of action studies:

  • Detailed investigation of how the peptide affects F11R-mediated signaling pathways

  • Analysis of effects on tight junction stability and endothelial barrier function

  • Confirmation that the peptide does not destabilize pre-existing tight junctions

• Pharmacokinetic and pharmacodynamic studies:

  • Determination of half-life and biodistribution

  • Establishment of optimal dosing regimens

  • Assessment of potential immunogenicity

• In vivo efficacy studies:

  • Testing in appropriate animal models of disease (e.g., mouse breast cancer models)

  • Evaluation of different administration routes

  • Long-term efficacy and safety monitoring

• Toxicology studies:

  • Comprehensive safety assessment in multiple species

  • Evaluation of potential off-target effects

  • Determination of maximum tolerated dose

Research has demonstrated that P4D effectively inhibits the adhesion and transendothelial migration of breast cancer cells to inflamed or Tβ4-treated endothelium without destabilizing pre-existing tight junctions in the endothelial monolayer . These findings support the potential of F11R-derived peptides as novel anti-metastatic therapeutics, though further in vivo and clinical studies are needed to fully evaluate their effectiveness .

What technical challenges exist in producing and validating F11R antibodies for research applications, and how can these be overcome?

Producing and validating F11R antibodies for research presents several technical challenges:

• Epitope selection complexities:

  • F11R contains multiple functional domains with distinct roles

  • Challenge: Targeting specific epitopes that will block desired functions without affecting others

  • Solution: Use structural data to design antibodies against specific regions like the cis-dimerization motif (R59V60E61) or trans-dimerization motif (N43N44P45)

• Specificity issues:

  • F11R shares structural similarities with other JAM family members

  • Challenge: Ensuring antibodies don't cross-react with related proteins

  • Solution: Rigorous validation using cells/tissues with knockout or overexpression of F11R and related proteins

• Conformational epitope recognition:

  • Native F11R protein has important conformational epitopes

  • Challenge: Many antibodies raised against linear peptides may not recognize native conformations

  • Solution: Use properly folded recombinant proteins or cell-based immunization strategies

• Application-specific validation requirements:

  • Different applications require distinct antibody properties

  • Challenge: An antibody effective for Western blotting may fail in flow cytometry or functional blocking

  • Solution: Comprehensive validation across multiple techniques including:

    • Flow cytometry using appropriate controls (e.g., FITC anti-human CD321/F11R antibody)

    • Western blotting with positive and negative control lysates

    • Immunofluorescence to confirm proper localization

    • Functional assays to verify blocking capability

• Clone selection and production variability:

  • Challenge: Batch-to-batch variability in antibody production

  • Solution: Develop recombinant antibodies with defined sequences or monoclonal antibodies with well-characterized hybridoma lines

• Validation in disease contexts:

  • F11R expression and conformation may be altered in pathological states

  • Challenge: Ensuring antibodies recognize disease-relevant forms of the protein

  • Solution: Validate antibodies using patient-derived samples or disease model systems

Researchers should implement a comprehensive validation pipeline that includes multiple techniques, appropriate controls, and functional verification to ensure antibody reliability across experimental contexts.

What controls are essential when studying cytokine-induced F11R expression in endothelial cells?

When studying cytokine-induced F11R expression in endothelial cells, several critical controls must be included to ensure valid and reliable results:

• Baseline expression controls:

  • Untreated endothelial cells to establish baseline F11R expression levels

  • Time-matched vehicle controls to account for potential time-dependent changes in expression

• Cytokine-specific controls:

  • Dose-response curves for each cytokine (e.g., TNF-α, IFN-γ) to determine optimal concentrations

  • Heat-inactivated cytokines to confirm that protein activity, not contaminants, is responsible for observed effects

  • Multiple cytokines tested individually and in combination to assess synergistic effects

• Transcriptional and translational controls:

  • RNA synthesis inhibitors (e.g., actinomycin D) to confirm de novo transcription rather than mRNA stabilization

  • Protein synthesis inhibitors to distinguish between new protein synthesis and redistribution of existing protein

  • Nuclear run-on assays or chromatin immunoprecipitation to directly assess transcriptional activation

• Signaling pathway controls:

  • Specific inhibitors of relevant signaling pathways (e.g., NF-κB, JAK/STAT) to elucidate mechanisms

  • Positive controls using known inducers of these pathways

• Cell type and condition controls:

  • Multiple endothelial cell types (e.g., HUVEC, HAEC) to account for potential vascular bed-specific differences

  • Assessment of cell confluence and passage number, as these can affect response to cytokines

  • Confirmation of endothelial phenotype using endothelial markers

• mRNA and protein measurement controls:

  • Multiple reference genes for qRT-PCR normalization

  • Loading controls for Western blotting (e.g., tubulin or GAPDH)

  • Isotype control antibodies for flow cytometry

• Functional outcome controls:

  • Correlation of F11R expression with functional outcomes such as platelet adhesion or transendothelial migration

  • F11R-siRNA to confirm that observed functional effects are specifically due to F11R induction

These controls collectively ensure that observed changes in F11R expression are specific, reproducible, and mechanistically linked to cytokine stimulation, rather than artifacts of experimental conditions or procedures .

How should researchers interpret contradictory findings between mRNA expression, protein levels, and functional outcomes in F11R studies?

Contradictions between mRNA expression, protein levels, and functional outcomes in F11R studies require systematic interpretation approaches:

• Temporal dynamics analysis:

  • mRNA induction typically precedes protein expression

  • Conduct detailed time-course experiments measuring both mRNA and protein at multiple timepoints

  • Consider that functional changes may lag behind both mRNA and protein changes

  • Solution: Create comprehensive temporal profiles spanning minutes to days to capture the full sequence of events

• Post-transcriptional regulation assessment:

  • Investigate microRNA regulation of F11R

  • Examine mRNA stability using actinomycin D chase experiments

  • Analyze polysome profiles to assess translational efficiency

  • Solution: Incorporate RNA-binding protein immunoprecipitation or ribosome profiling to identify regulatory mechanisms

• Post-translational modification evaluation:

  • F11R function is modified by phosphorylation and glycosylation

  • The D2 domain contains a single N-glycan at N185 residue that stabilizes F11R homodimers and influences function

  • Solution: Employ phospho-specific antibodies, glycosylation inhibitors, or mass spectrometry to characterize modifications

• Protein localization verification:

  • F11R function depends on subcellular localization

  • Protein may be abundant but not correctly localized to exert its function

  • Solution: Use subcellular fractionation and immunofluorescence microscopy to track F11R redistribution between junctional and luminal surfaces

• Soluble versus membrane-bound form quantification:

  • Measure soluble F11R/JAM-A levels in media from cultured cells

  • Solution: Use both ELISA for soluble forms and flow cytometry for membrane expression to create a complete picture

• Functional assay sensitivity considerations:

  • Different functional assays have varying sensitivity thresholds

  • Small changes in protein levels may produce significant functional effects if they occur at critical locations

  • Solution: Use multiple complementary functional assays with different detection principles

• Experimental context integration:

  • Consider how experimental conditions (confluent versus subconfluent cells, inflammatory state, etc.) affect the relationship between expression and function

  • Solution: Standardize experimental conditions and explicitly report these details

When interpreting contradictory findings, researchers should avoid oversimplified models that assume linear relationships between mRNA, protein, and function. Instead, they should develop integrated models that account for the complex regulatory mechanisms operating at multiple levels .

What are the most promising applications of F11R as a biomarker or therapeutic target in precision medicine?

F11R shows considerable promise in several precision medicine applications:

• Cancer metastasis prevention:

  • F11R-derived peptides like peptide 4D (P4D) demonstrate significant potential as anti-metastatic agents by blocking cancer cell transendothelial migration

  • Targeting F11R could specifically inhibit cancer cell adhesion to endothelium without disrupting normal endothelial barrier function

  • The ability of P4D to inhibit breast cancer cell adhesion and migration without destabilizing pre-existing tight junctions makes it particularly promising

• Cardiovascular disease biomarker development:

  • Soluble F11R/JAM-A levels in plasma could serve as indicators of endothelial activation and inflammation

  • Monitoring F11R expression levels could help identify patients at risk for atherosclerosis before clinical manifestations

  • The critical role of F11R in the initiation of atherogenesis suggests potential for early intervention targeting this pathway

• Personalized cancer therapy selection:

  • F11R expression patterns vary across cancer types, suggesting potential for use in cancer classification and therapy selection

  • High F11R expression in certain breast cancers correlates with poor outcomes, potentially identifying patients who would benefit from F11R-targeted therapies

  • Monoclonal antibodies against F11R have shown promise in reducing murine breast tumor xenograft growth

• Inflammatory disease intervention:

  • F11R's involvement in inflammatory processes suggests applications in conditions like inflammatory bowel disease and rheumatoid arthritis

  • Targeted inhibition could provide more specific anti-inflammatory effects with fewer side effects than current broad-spectrum approaches

• Blood-brain barrier modulation:

  • F11R's role in tight junction regulation suggests applications in drug delivery across the blood-brain barrier

  • Temporary, controlled modulation of F11R function could enhance CNS drug penetration in neurological disorders

The most immediate clinical translation opportunities appear to be in breast cancer metastasis prevention and cardiovascular disease risk assessment, where the mechanistic understanding and experimental validation are most advanced .

How might single-cell analysis technologies enhance our understanding of F11R expression heterogeneity in complex tissues?

Single-cell analysis technologies offer transformative potential for understanding F11R expression heterogeneity:

• Cell type-specific expression patterns:

  • Single-cell RNA sequencing (scRNA-seq) can reveal differential F11R expression across diverse cell populations within tissues

  • This approach could identify previously unrecognized F11R-expressing cell types or subpopulations

  • Important application: Mapping F11R expression across all cell types in tumor microenvironments to identify potential therapeutic targets

• Spatial distribution analysis:

  • Spatial transcriptomics or multiplexed immunofluorescence can map F11R expression patterns within tissue architecture

  • This reveals how F11R expression relates to structural features like blood vessels, inflammatory foci, or tumor boundaries

  • Critical for understanding: How F11R expression at specific tissue locations (e.g., tumor invasion front) correlates with disease progression

• Temporal dynamics during disease progression:

  • Single-cell trajectory analysis can reveal how F11R expression changes as cells transition through disease states

  • This approach could identify the precise timing of F11R upregulation during inflammatory responses or metastatic cascade

  • Application: Determining optimal timing for therapeutic intervention targeting F11R

• Co-expression network analysis:

  • Single-cell multi-omics approaches can correlate F11R expression with other proteins, signaling pathways, and epigenetic states

  • This reveals regulatory relationships and functional interactions at individual cell level

  • Importance: Identifying potential combination therapy targets by finding genes co-expressed with F11R in pathological states

• Rare cell population identification:

  • Single-cell technologies can identify rare cell populations with unique F11R expression patterns

  • These might include cancer stem cells, therapy-resistant clones, or specialized immune cells

  • Application: Developing strategies to target these rare but potentially disease-driving cell populations

• Response to treatment monitoring:

  • Single-cell analysis before and after treatment can reveal cell type-specific responses in F11R expression

  • This approach could identify resistant cell populations that maintain F11R expression despite therapy

  • Critical for: Developing adaptive treatment strategies that overcome resistance mechanisms

Implementation of these technologies could resolve contradictions in current F11R research by revealing how heterogeneous expression patterns within complex tissues drive apparently conflicting observations in bulk analysis studies.